The aim of this meta-analysis was to assess the effects of probiotic consumption on the lipid profiles of hypercholesterolemic patients in randomized controlled trials (RCT). We performed systematic searches in The Cochrane Library, Web of Science, Medline and Google Scholar for relevant studies published up to March 2020. Of the 2346 reports that were screened, 13 randomized clinical trials were selected. The pooled data revealed that probiotic supplementation significantly (p < 0.05) decreased total cholesterol (TC) [n = 20; standardized mean difference (SMD) = −0.30; 95% confidence interval (CI): −0.43, −0.16; p < 0.0001] and low-density lipoprotein cholesterol (LDL-C) levels (n = 20; SMD = −0.32; 95% CI: −0.46, −0.19; p < 0.00001) in hypercholesterolemic patients. We found that the administration of probiotics counteracted some aspects of dyslipidemia in hypercholesterolemic patients.

这项荟萃分析的目的是在随机对照试验（RCT）中评估食用益生菌对高胆固醇血症患者脂质谱的影响。我们在Cochrane图书馆，Web of Science，Medline和Google Scholar中进行了系统的搜索，以查找截至2020年3月的相关研究。在筛选的2346份报告中，选择了13项随机临床试验。汇总的数据显示，补充益生菌可显着降低（p  <0.05）总胆固醇（TC）[n = 20; 标准化平均差（SMD）= -0.30; 95％置信区间（CI）：-0.43，-0.16; p  <0.0001]和低密度脂蛋白胆固醇（LDL-C）水平（n = 20； SMD = -0.32； 95％CI：-0.46，-0.19；p <0.00001）在高胆固醇血症患者中。我们发现，益生菌的使用可以抵消高胆固醇血症患者血脂异常的某些方面。